PropertyValue
?:abstract
  • Compared with regulatory agencies overseas, it is a very long and very expensive proposition to gain FDA approval to market a new drug or device [ ]in the United States we don\'t have a POC C-reactive protein (CRP) device that could help management of respiratory infections [ ]insurance companies have restricted access to better POC diagnostic studies by refusing to pay for more accurate tests when less-expensive (and less-accurate) tests are covered
is ?:annotates of
?:creator
?:journal
  • Contemporary_Pediatrics
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • COVID-19: Thoughts while circling the wagons
?:type
?:who_covidence_id
  • #831157
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/1gt4sqao>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/1gt4sqao>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all